Targeting IDH mutation: another milestone, but not the finish line
Mené sur 331 patients atteints d'un gliome de faible grade avec mutation IDH1 ou IDH2 (durée médiane de suivi : 20,1 mois), cet essai international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du vorasidénib
Targeted therapy has entered the stage of glioma management. Mutated isocitrate dehydrogenase (IDH) is the molecular hallmark of WHO grade 2 diffuse low-grade gliomas. In The Lancet Oncology, Timothy F Cloughesy and colleagues compared the mutated IDH inhibitor vorasidenib with placebo for diffuse low-grade gliomas without high-risk features, with 6 months' additional follow-up.1 As expected with the short additional follow-up, this study supports the results of progression-free survival, time to next intervention, and adverse events from the phase 3 trial (INDIGO).2 The most interesting new aspects are the analyses of tumour volumes, in addition to patient-centred results on cognition, health-related quality of life (HRQOL), and seizure outcome.
The Lancet Oncology , commentaire, 2025